Novo Nordisk

News

Pfizer selects once-daily GLP-1 for its obesity push

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.

News

FDA rejects Novo Nordisk’s weekly basal insulin

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US.

News

Lilly scores against Novo Nordisk in weight loss contest

There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be

News

Four drugmakers found to have breached ABPI code

Novartis, Pfizer, Otsuka and Novo Nordisk have been called out by the UK’s Prescription Medicines Code of Practice Authority (PMCPA) for breaching the Association of the British Pharmaceuti

News

Study links Ozempic/Wegovy to sight-threatening disorder

Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.

News

Novo Nordisk's site in Clayton, North Carolina

Novo Nordisk pledges $4.1bn for US injectables plant

Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facilit

Pfizer selects once-daily GLP-1 for its obesity push

FDA rejects Novo Nordisk’s weekly basal insulin

Lilly scores against Novo Nordisk in weight loss contest

Four drugmakers found to have breached ABPI code

Study links Ozempic/Wegovy to sight-threatening disorder

Novo Nordisk pledges $4.1bn for US injectables plant

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

Novo Nordisk

Editor's Picks